Vimarsana
Biggest News Aggregation in the World

John Mullaly News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Mullaly. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Mullaly Today - Breaking & Trending Today

CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants - Vimarsana News

CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants

The current market for breast implants is estimated at $2.6 billion a yearCollPlant expects the study to conclude by the first half of 2024CollPlant plans to use findings from this study and...

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments - Vimarsana News

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

NEW YORK, Dec. 26, 2023 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant...

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 18, 2023 -- Jasper Therapeutics, Inc. , a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit in mast cell-driven...

Kineta to Present at the Life Sciences Investor Forum December 14th - Vimarsana News

Kineta to Present at the Life Sciences Investor Forum December 14th

SEATTLE, Dec. 12, 2023 -- Kineta, Inc. , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced...

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 - Vimarsana News

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

REDWOOD CITY, Calif., Dec. 10, 2023 -- Jasper Therapeutics, Inc. , a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell...